Because RNF43 loss‐of‐function mutations and KRAS gain‐of‐function mutations concur in a subset of IPMN and PDAC, their biological significance and therapeutic potential should be elucidated. This evidence concerns the gene RNF43 and pancreatic intraductal papillary-mucinous neoplasm.